The radiopharmaceutical, already approved for SSRT-expressing GEP-NETs, may be a new option in meningioma if future research ...
The firm said it will discuss biomarker results, including a marked decrease in N-acetylaspartate levels and an increase in brain white matter.
Prevail will buy $350,000 worth of shares in Hemogenyx and will serve as a contract research organization for an upcoming clinical trial in pediatric leukemia.